
Amplitude Surgical (AMPLI) | Financial Analysis & Statements
Amplitude Surgical S.A.S. | Mid-cap | Healthcare
Amplitude Surgical S.A.S. | Mid-cap | Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
279.3M
Total Liabilities
183.4M
Shareholders Equity
95.8M
Debt to Equity
1.91
Cash Flow Metrics
Revenue & Profitability Trend
Amplitude Surgical Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 106.0M | 100.2M | 87.6M | 82.7M | 88.3M |
Cost of Goods Sold | 22.3M | 21.2M | 20.3M | 19.0M | 22.7M |
Gross Profit | 83.7M | 79.0M | 67.3M | 63.7M | 65.6M |
Gross Margin % | 78.9% | 78.9% | 76.8% | 77.0% | 74.3% |
Operating Expenses | |||||
Research & Development | 1.9M | 1.5M | 1.4M | 1.4M | 958.0K |
Selling, General & Administrative | 16.6M | 16.0M | 14.5M | 13.4M | 13.3M |
Other Operating Expenses | 12.3M | 11.1M | 13.5M | 11.0M | 5.4M |
Total Operating Expenses | 30.8M | 28.7M | 29.4M | 25.8M | 19.6M |
Operating Income | 12.9M | 10.9M | 1.7M | -1.3M | -1.5M |
Operating Margin % | 12.2% | 10.8% | 1.9% | -1.6% | -1.7% |
Non-Operating Items | |||||
Interest Income | 2.9M | 1.6M | 3.9M | 160.0K | 1.3M |
Interest Expense | 10.1M | 11.1M | 9.3M | 9.6M | 6.6M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 1.6M | -6.0M | -1.6M | -11.5M | -11.3M |
Income Tax | 92.0K | 769.0K | 1.2M | 1.9M | 3.3M |
Effective Tax Rate % | 5.7% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | 1.5M | 38.5M | -4.8M | -14.4M | -14.6M |
Net Margin % | 1.4% | 38.4% | -5.5% | -17.4% | -16.6% |
Key Metrics | |||||
EBITDA | 22.8M | 17.8M | 20.3M | 16.3M | 17.4M |
EPS (Basic) | - | €0.82 | €-0.09 | €-0.30 | €-0.30 |
EPS (Diluted) | - | €0.82 | €-0.09 | €-0.30 | €-0.30 |
Basic Shares Outstanding | - | 48021000 | 48021000 | 47805000 | 47805000 |
Diluted Shares Outstanding | - | 48021000 | 48021000 | 47805000 | 47805000 |
Income Statement Trend
Amplitude Surgical Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 29.1M | 37.2M | 21.0M | 30.7M | 36.7M |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 14.8M | 11.1M | 10.6M | 17.0M | 8.2M |
Inventory | 43.3M | 38.0M | 32.9M | 44.5M | 41.5M |
Other Current Assets | 476.0K | 881.0K | 909.0K | -1.0K | 275.0K |
Total Current Assets | 94.7M | 95.5M | 96.7M | 94.4M | 93.1M |
Non-Current Assets | |||||
Property, Plant & Equipment | 50.7M | 29.2M | 29.5M | 28.7M | 29.3M |
Goodwill | 234.9M | 223.1M | 219.4M | 220.6M | 223.7M |
Intangible Assets | 37.3M | 31.8M | 28.0M | 29.2M | 32.3M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | - | -2.0K | -1.0K | -1.0K | - |
Total Non-Current Assets | 184.6M | 170.6M | 162.8M | 174.6M | 182.1M |
Total Assets | 279.3M | 266.0M | 259.5M | 269.1M | 275.2M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 15.1M | 15.5M | 11.4M | 26.8M | 11.1M |
Short-term Debt | 17.1M | 11.3M | 11.7M | 9.0M | 20.5M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 2.0M | 2.4M | 2.2M | 2.6M | 1.8M |
Total Current Liabilities | 46.9M | 41.3M | 43.8M | 38.4M | 46.2M |
Non-Current Liabilities | |||||
Long-term Debt | 102.0M | 95.2M | 127.3M | 137.7M | 123.9M |
Deferred Tax Liabilities | 2.1M | 1.7M | 1.7M | 2.1M | 1.5M |
Other Non-Current Liabilities | 1.0K | - | 2.0K | 18.8M | 213.0K |
Total Non-Current Liabilities | 136.5M | 128.9M | 163.1M | 173.8M | 158.1M |
Total Liabilities | 183.4M | 170.2M | 206.9M | 212.2M | 204.3M |
Equity | |||||
Common Stock | 480.0K | 480.0K | 480.0K | 478.0K | 478.0K |
Retained Earnings | 1.5M | 39.2M | -4.4M | -14.1M | -14.2M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 95.8M | 95.8M | 52.6M | 56.9M | 70.9M |
Key Metrics | |||||
Total Debt | 119.1M | 106.5M | 139.1M | 146.8M | 144.4M |
Working Capital | 47.7M | 54.1M | 52.8M | 56.0M | 46.8M |
Balance Sheet Composition
Amplitude Surgical Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 1.5M | 38.5M | -4.8M | -14.7M | -14.6M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | 0 | 139.0K | 185.0K |
Working Capital Changes | -6.8M | 6.4M | -1.7M | -6.2M | 8.2M |
Operating Cash Flow | -5.3M | 44.9M | -6.5M | -20.8M | -6.3M |
Investing Activities | |||||
Capital Expenditures | -10.4M | -11.2M | -5.2M | -5.1M | -5.1M |
Acquisitions | - | - | - | - | 67.0K |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -12.1M | 53.7M | -5.7M | -5.1M | -4.9M |
Financing Activities | |||||
Share Repurchases | -59.0K | - | - | - | -105.0K |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 9.4M | 11.9M | 2.0M | 105.7M | 20.0M |
Debt Repayment | -9.9M | -48.8M | -7.9M | -102.8M | -6.0M |
Financing Cash Flow | 2.5M | -37.4M | -5.5M | 3.4M | 14.3M |
Free Cash Flow | -14.9M | -11.3M | -4.2M | -7.1M | 2.6M |
Net Change in Cash | -14.9M | 61.2M | -17.7M | -22.5M | 3.1M |
Cash Flow Trend
Amplitude Surgical Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
310.00
Price to Book
3.14
Price to Sales
2.74
Profitability Ratios
Profit Margin
1.00%
Operating Margin
11.52%
Return on Equity
1.15%
Return on Assets
3.10%
Financial Health
Current Ratio
1.91
Debt to Equity
126.32
Beta
0.13
Per Share Data
EPS (TTM)
€0.02
Book Value per Share
€1.97
Revenue per Share
€2.26
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
ampli | 297.4M | 310.00 | 3.14 | 1.15% | 1.00% | 126.32 |
EssilorLuxottica | 123.5B | 51.90 | 3.26 | 6.44% | 8.74% | 36.58 |
Sartorius Stedim | 17.3B | 76.84 | 4.40 | 5.69% | 7.78% | 73.51 |
Crossject S.A | 85.4M | - | - | 478.68% | 0.00% | -7.88 |
Visiomed Group SA | 53.2M | 57.80 | 2.10 | 3.68% | 6.58% | 32.03 |
Bonyf N.V | 7.8M | - | 17.50 | -1.38% | 8.02% | 0.00 |
Financial data is updated regularly. All figures are in the company's reporting currency.